What if a clinical scan could transform biopharmaceutical innovation and patient care, streamlining drug development, clinical trials, and complex disease diagnosis? Total-body Positron Emission Tomography (PET) imaging is turning that vision into reality, offering a full-body, real-time view of human physiology.
Total-body PET is redefining what is possible in molecular imaging and biopharmaceutical development. This advanced PET technology can deliver full-body scans in minutes, with a sensitivity of up to 40x greater than conventional standard field PET scanners1 potential for significantly lower radiation exposure. This opens exciting new avenues for research and discovery. It enables clinicians to study disease in real time across the whole body, revolutionising how we diagnose, stage and treat complex conditions like cancer, cardiovascular disease and neurodegenerative disorders. For patients, this means faster scans and earlier interventions, with the opportunity for more personalised treatments. For research and industry, it unlocks a powerful new platform for evaluating novel therapies, tracking their behaviour and accelerating their path to market.
But realising the full potential of total-body PET requires more than cutting-edge scanners. It demands a robust infrastructure, one that includes a reliable supply of radiotracers and an integrated framework for data sharing and collaboration. In the UK, the National PET Imaging Platform (NPIP) is building exactly that. What it reveals is not just a clearer image of the body, but a blueprint for the future of biopharmaceutical development.
